AKUMS

Akums Drugs & Pharmaceuticals Share Price

 

 

Invest in Akums Drugs & Pharmaceuticals with 3.21X leverage

Invest with MTF

Performance

  • Low
  • ₹450
  • High
  • ₹462
  • 52 Week Low
  • ₹405
  • 52 Week High
  • ₹810
  • Open Price₹459
  • Previous Close₹460
  • Volume449,950

Investment Returns

  • Over 1 Month + 2.73%
  • Over 3 Month -6.92%
  • Over 6 Month -11.57%
  • Over 1 Year -43.89%

Smart Investing Starts Here Start SIP with Akums Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Akums Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 20.9
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 7,136
  • P/B Ratio
  • 2.3
  • Average True Range
  • 12.32
  • EPS
  • 20.92
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.08
  • RSI
  • 43.91
  • MFI
  • 41.17

Akums Drugs & Pharmaceuticals Financials

Akums Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹453.35
-7 (-1.52%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹461.62
  • 50 Day
  • ₹468.68
  • 100 Day
  • ₹489.28
  • 200 Day
  • ₹547.01

Resistance and Support

454.95 Pivot Speed
  • R3 472.90
  • R2 467.45
  • R1 460.40
  • S1 447.90
  • S2 442.45
  • S3 435.40

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Akums Drugs & Pharmaceuticals Ltd. is India’s leading contract manufacturing company, producing a wide range of pharmaceutical and nutraceutical products. It provides end-to-end solutions, including formulation development, manufacturing, and packaging for domestic and global clients.

Akums Drugs And Pharmaceuticals Ltd has an operating revenue of Rs. 4,123.08 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of 8% is okay, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 38 which is a POOR score indicating inconsistency in earnings, a RS Rating of 22 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 153 indicates it belongs to a poor industry group of Medical-Products and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Akums Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-08-08 Quarterly Results
2025-05-26 Audited Results
2025-02-06 Quarterly Results
2024-11-09 Quarterly Results
2024-08-24 Quarterly Results

Akums Drugs & Pharmaceuticals F&O

Akums Drugs & Pharmaceuticals Shareholding Pattern

75.26%
6.44%
0.63%
2.27%
5.01%
10.39%

About Akums Drugs & Pharmaceuticals

  • NSE Symbol
  • AKUMS
  • BSE Symbol
  • 544222
  • Managing Director
  • Mr. Sanjeev Jain
  • ISIN
  • INE09XN01023

Similar Stocks to Akums Drugs & Pharmaceuticals

Akums Drugs & Pharmaceuticals FAQs

Akums Drugs & Pharmaceuticals share price is ₹453 As on 08 November, 2025 | 06:28

The Market Cap of Akums Drugs & Pharmaceuticals is ₹7135.5 Cr As on 08 November, 2025 | 06:28

The P/E ratio of Akums Drugs & Pharmaceuticals is 20.9 As on 08 November, 2025 | 06:28

The PB ratio of Akums Drugs & Pharmaceuticals is 2.3 As on 08 November, 2025 | 06:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23